Abstracts tagged "DMARDs"

Abstract Number: 389 • 2017 ACR/ARHP Annual Meeting
S-110483 a New Potent EP4 Receptor Antagonist with Immunomodulatory and Analgesic Activities
Takashi Maeda¹, Toshitaka Ochiai², Toshie Nagayasu-Tanaka¹, Yuta Morisaki¹, Haruka Takizawa¹, Seiji Ishihara¹, Shigeo Kurokawa¹, Kiyoharu Ukai¹ and Masahiro Suda¹, ¹Pharmacology Department, Kaken Pharmaceutical Co., LTD, Kyoto, Japan, ²Kaken Pharmaceutical Co., LTD, Kyoto, Japan
Background/Purpose: Prostaglandin (PG) E2 is known to enhance the expansion of T helper 17 (Th17) cell population via EP4 receptor (EP4) in the early phase…
Abstract Number: 1159 • 2017 ACR/ARHP Annual Meeting
National Recommendations on the Use of Immunomodulatory Drugs in Patients with NON-Infectious NON-Malignant Anterior Uveitis
Gerard Espinosa¹, Santiago Muñoz², Jose M Ruiz de Morales³, Jose M Herreras⁴ and Miguel Cordero-Coma⁵, ¹Autoimmune Diseases Department. Hospital Clínic de Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Infanta Sofia, Madrid, Spain, ³Complejo Asistencial Universitario de León, León, Spain, ⁴Ophthalmology, Hospital Universitario, IOBA, Valladolid, Spain, ⁵Ophthalmology, Hospital de León. Spain, León, Spain
Background/Purpose: Anterior uveitis (AU) is the most common pattern of uveitis, that migh lead to important ocular complications including blindness. Immunomodulatory drugs have been used…
Abstract Number: 2404 • 2017 ACR/ARHP Annual Meeting
Use of Dmards after the Diagnosis of Cancers in Patients with RA
Young Bin Joo, Yune-Jung Park, Ki-Jo Kim and Kyung-Su Park, Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea, Republic of (South)
Background/Purpose: Although there are many studies about the association of disease-modifying anti-rheumatic drugs (DMARDs) with cancers in patients with rheumatoid arthritis (RA), there are few…
Abstract Number: 390 • 2017 ACR/ARHP Annual Meeting
S-110483, a Novel and Selective EP4 Receptor Antagonist with Anti-Bone Destruction Activities
Toshitaka Ochiai¹, Takashi Maeda², Toshie Nagayasu-Tanaka², Jun Anzai¹, Daiki Kato¹, Yuta Morisaki², Kiyoharu Ukai² and Masahiro Suda², ¹Kaken Pharmaceutical Co., LTD, Kyoto, Japan, ²Pharmacology Department, Kaken Pharmaceutical Co., LTD, Kyoto, Japan
Background/Purpose: S-110483 is our novel potent and selective EP4 receptor (EP4) antagonist. In addition to the well-known fact that EP4 antagonists have anti-inflammatory effects, it…
Abstract Number: 1311 • 2017 ACR/ARHP Annual Meeting
Pregnancy Outcome in Chinese Women with Rheumatic Disease Treated By Leflunomide (LEF)
Yan Zhao¹, lingxun shen², zongwen shuai³, Hengli Zhao⁴, Weinan Lai⁵, Xiaoling Lai⁶, Shaoying Zhang⁷, Xuequn Wang⁸, Shaoxian Hu⁹, Wenli Chen¹⁰, Wei Ji¹¹, Hua Wei¹², Qi Zhang¹³, Lixia Pang¹⁴, huaxiang Liu¹⁵, Qiang Shu¹⁵, Jun-li Zhang¹⁶, Yating Zhou¹⁷, Qiong Jiang¹⁸, Huaxiang Wu¹⁹, Jing Xue¹⁹, Ganping Bai²⁰, Li Zhang²¹ and Fei Xiao²¹, ¹Rheumatology, Peking Union Medical College Hospital, Beijing, China, ²Wuhan Union Hospital, wuhan, China, ³The First Affiliated Hospital of Anhui University, Hefei, China, ⁴Yantai Hospital of Traditional medicine University, Yantai, China, ⁵Nanfang Hospital, Guangzhou, China, ⁶Guangxi Hospital of Traditional Chinese Medicine, Nanning, China, ⁷Yiling Hospital, Yiling, China, ⁸The First Affiliated Hospital of Xinyang, Xinyang, China, ⁹Tongji hospital, wuhan, China, ¹⁰Wuhan Central Hospital, wuhan, China, ¹¹Jiangsu Province Hospital of TCM, Nanjing, China, ¹²Subei People's Hospital, Yangzhou, China, ¹³Dongying central hospital, Dongying, China, ¹⁴Dongying Hospital, Dongying, China, ¹⁵Qilu hospital of Shandong University, Jinan, China, ¹⁶Rheumatology, The Fifth Hospital of Xi’an City, Xi’an, China, ¹⁷Xian No5 Hospital, Shandong, China, ¹⁸Taizhou Hospital, Taizhou, China, ¹⁹The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, ²⁰Chongqing Southwest Hospital, Chongqing, China, ²¹Gothic Internet Technology Corporation, Shanghai, China
Background/Purpose: LEF is a first line DMARD. Due to the teratogenic effects in offspring of rats in preclinical study, the patients who plan to get…
Abstract Number: 2469 • 2017 ACR/ARHP Annual Meeting
Median Time to Lda Is Shorter in Tocilizumab Combination Therapy with Csdmards As Compared to Monotherapy in Patients with Active Rheumatoid Arthritis and Inadequate Responses to Csdmards and/or TNF Inhibitors: Sub-Analysis of the Swiss and Austrian Patients from the ACT-SURE Study
Ruediger Mueller¹, Winfried Graninger², Páris Sidiropoulos³, Christoph Goger⁴ and Johannes von Kempis⁵, ¹Rheumatology, MD, St. Gallen, Switzerland, ²Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ³F. Hoffmann-La Roche Ltd, South San Francisco, CA, ⁴Roche Austria GmbH, Vienna, Austria, ⁵Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland
Background/Purpose: To analyze efficacy and safety of tocilizumab in patients with rheumatoid arthritis (RA) and an inadequate response to conventional synthetic disease modifying anti-rheumatic drugs…
Abstract Number: 152 • 2017 Pediatric Rheumatology Symposium
Characteristics of Patients With Juvenile Idiopathic Arthritis in a US Healthcare Claims Database
TA Simon¹, A Baheti², N Ray², S Kelly¹ and Z Guo¹, ¹Bristol-Myers Squibb, Princeton, NJ, ²Mu Sigma, Bangalore, India
Background/Purpose: Abatacept, the first selective co-stimulation modulator approved and used for the treatment of juvenile idiopathic arthritis (JIA), has a mechanism of action that is…
Abstract Number: 1728 • 2016 ACR/ARHP Annual Meeting
Comparison of Adherence to Disease Modifying Antirheumatic Drugs in Psoriatic Arthritis and Other Rheumatic Disease
Mehmet Ali Balci¹, Mustafa Ferhat Oksuz², Salim Donmez¹, Tugce Ozen³, Ediz Dalkilic², Ayse Nur Tufan², Yavuz Pehlivan² and Omer Nuri Pamuk⁴, ¹Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, ²Rheumatology, Uludag University Medcal Faculty, Bursa, Turkey, ³PHYSICAL THERAPY AND REHABILITATION, Trakya University Faculty of Health Sciences, Edirne, Turkey, ⁴Rheumatology, Department of Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, Edirne, Turkey
Background/Purpose: Psoriatic arthritis (PsA), Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are an inflammatory arthritis causing joint damage and disability. Non-adherence to disease modifying anti-rheumatic…
Abstract Number: 2525 • 2016 ACR/ARHP Annual Meeting
Patient Characteristics Predicting Remission Using Intensive Treatment Strategies in Early Rheumatoid Arthritis
Diederik Decock¹, Rene Westhovens^1,2, Veerle Stouten¹, Kristien Van der Elst^2,3, Johan Joly², Patrick Verschueren^1,2 and CareRA study group, ¹KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium, ²Rheumatology, University Hospitals Leuven, Leuven, Belgium, ³KU Leuven, Department of Public Health and Primary Care, Skeletal Biology and Engineering Research Center, Leuven, Belgium
Background/Purpose: Guidelines recommend to treat newly diagnosed Early Rheumatoid Arthritis (ERA) with intensive treatment strategies using Methotrexate (MTX) or a combination of csDMARDs and a…
Abstract Number: 20 • 2016 ACR/ARHP Annual Meeting
Diabetes and Other Comorbidities in Rheumatoid Arthritis Patients Starting a Biologic DMARD: A Multi-Database Cohort Study
Seoyoung C. Kim^1,2, Yinzhu Jin³, Gregory Brill⁴, Jennifer Lewey^4,5, Nam-Kyong Choi³, Elisabetta Patorno⁴ and Rishi J. Desai³, ¹Rheumatology, Immunology and Allergy and Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ²Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ³Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, ⁵Division of Cardiology, Columbia University Medical Center, New York, NY
Background/Purpose: Patients with rheumatoid arthritis (RA) are known to have an increased comorbidity burden. Presence of diabetes or other comorbidities such as cardiovascular disease (CVD)…
Abstract Number: 1735 • 2016 ACR/ARHP Annual Meeting
Canadian Humira Post-Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis (Complete-PsA): Interim Analysis
Majed Khraishi¹, Boulos Haraoui², Louis Bessette^3,4, Yatish Setty⁵, William G. Bensen⁶ and Valencia P. Remple^7,8, ¹Department of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada, ³Faculty of Medicine, Laval University, Quebec, QC, Canada, ⁴Centre Hospitalier de l'Université Laval, Quebec, QC, Canada, ⁵Grey Bruce Health Services, Owen Sound, ON, Canada, ⁶Department of Medicine, Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ⁷AbbVie Corporation, Montreal, QC, Canada, ⁸School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: COMPLETE-PsA is an ongoing observational study planning to enroll 670 psoriatic arthritis (PsA) patients (pts) from ~40 sites across Canada. Main objectives are to…
Abstract Number: 2554 • 2016 ACR/ARHP Annual Meeting
Changes in Blood Pressure Following the Initiation of Disease Modifying Therapies in US Veterans with Rheumatoid Arthritis
Joshua Baker¹, Brian Sauer², Chia-Chen Teng³, Grant W. Cannon⁴, Said Ibrahim⁵, Michael George⁶, Amy C. Cannella⁷, Bryant R. England⁸, Liron Caplan⁹, Lisa A. Davis¹⁰, Kaleb Michaud¹¹, James R. O'Dell¹² and Ted R Mikuls¹³, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²IDEAS Center and Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ³Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁴Salt Lake City VA Medical Center and University of Utah Division of Rheumatology, Salt Lake City, UT, ⁵Medicine, University of Pennsylvania, Philadelphia, PA, ⁶Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁷Section of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁸Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁹Denver Veterans Affairs Medical Center and UC Denver SOM, Denver, CO, ¹⁰Div of Rheumatology, Univ of CO Denver School of Med, Aurora, CO, ¹¹University of Nebraska Medical Center, Omaha, NE, ¹²Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ¹³Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Chronic inflammation is associated with a greater risk of hypertension (HTN) while inflammatory cytokines such as TNF-α have been shown to have vasodilator effects.…
Abstract Number: 97 • 2016 ACR/ARHP Annual Meeting
Effects of DMARD Tapering on Treatment Costs and Work Productivity in Rheumatoid Arthritis Patients- an Analysis from the Prospective Randomized Controlled Retro- Study
Melanie Hagen¹, Camille P Figueiredo², Jayme Fogagnolo Cobra³, Judith Haschka⁴, Michaela Reiser⁵, Matthias Englbrecht⁶, Axel J. Hueber⁷, Bernhard Manger⁶, Arnd Kleyer⁸, Stephanie Finzel⁹, Hans-Peter Tony¹⁰, Stefan Kleinert¹¹, Joerg Wendler¹², Florian Schuch¹², Monika Ronneberger¹², Martin Feuchtenberger¹³, Martin Fleck¹⁴, Karin Manger¹⁵, Wolfgang Ochs¹⁶, Matthias Schmitt-Haendle¹⁷, H.-M. Lorenz¹⁸, HG Nüßlein¹⁹, R Alten²⁰, Joerg C. Henes²¹, Klaus Krüger²², Georg Schett⁷ and Juergen Rech⁷, ¹Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany, ²Rheumatology Division, Faculdade de Medicina da USP, São Paulo, Brazil, ³Instituto de Reumatologia de Sao Paolo, Sao Paolo, Brazil, ⁴Medical Department II, St. Vincent Hospital, the VINFORCE Study Group, Academic Teaching Hospital of Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁵Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ⁶Department of Internal Medicine 3, Rheumatology & Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁷Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁸Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁹Rheumatology and Clinical Immunology, University Medical Center Freiburg, Freiburg, Freiburg, Germany, ¹⁰Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Würzburg, Germany, ¹¹Rheumatologische Schwerpunktpraxis Erlangen, Erlangen, Germany, ¹²Schwerpunktpraxis Rheumatologie, Erlangen, Germany, ¹³Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, ¹⁴Department of Internal Medicine I, University of Regensburg, 93042 Regensburg, Germany, ¹⁵Rheumatology Practice Bamberg, Bamberg, Germany, ¹⁶Internistisch-rheumatologische Praxisgemeinschaft Bayreuth, Bayreuth, Germany, ¹⁷Rheumatology Practice, Bayreuth, Germany, Bayreuth, Germany, ¹⁸Im Neuenheimer Feld 41, UNI-Klinikum Heidelberg, Medizinische Klinik,, Heidelberg, Germany, ¹⁹University of Erlangen, Nürnberg, Germany, ²⁰Rheumazentrum Ruhrgebiet, Herne, Germany, ²¹Department of Internal Medicine II, Division of Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, ²²Praxiszentrum St. Bonifatius, München, Germany
Effects of DMARD Tapering on Treatment Costs and Work Productivity in Rheumatoid Arthritis Patients- an Analysis from the Prospective Randomized Controlled RETRO- Study Background/Purpose: Achieving remission…
Abstract Number: 1956 • 2016 ACR/ARHP Annual Meeting
High Dose Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Tumor Necrosis Factor Inhibitor Use Results in Less Radiographic Progression in Ankylosing Spondylitis – a Longitudinal Analysis
Lianne S. Gensler¹, John D. Reveille², MinJae Lee³, Thomas Learch⁴, Matthew Brown⁵, Mohammad H. Rahbar³, Michael Weisman⁶ and Michael Ward⁷, ¹Medicine/Rheumatology, UCSF, San Francisco, CA, ²Rheumatology, University of Texas-McGovern Medical School, Houston, TX, ³Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas-McGovern Medical School, Houston, TX, ⁴Radiology, Cedars Sinai Medical Center, Los Angeles, CA, ⁵Queensland University of Technology, Brisbane, Australia, ⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷NIH/NIAMS, Bethesda, MD
Background/Purpose: Over the last decade, the disease modifying effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Tumor Necrosis Factor inhibitors (TNFi) have resulted in conflicting studies. …
Abstract Number: 2555 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Conventional and Targeted Synthetic Disease-Modifying Antirheumatic Drugs As Well As Glucocorticoids: A Systematic Literature Review Informing the 2016 Update of the Eular Recommendations for the Management of Rheumatoid Arthritis
Katerina Chatzidionysiou¹, Sharzad Emamikia², Jackie L. Nam³, Sofia Ramiro⁴, Josef Smolen⁵, Désirée van der Heijde⁶, Maxime Dougados⁷, Johannes WJ Bijlsma⁸, Gerd Burmester⁹, Marieke Scholte-Voshaar¹⁰, Ronald van Vollenhoven^11,12 and Robert Landewé¹³, ¹Karolinska Institute, Stockholm, Sweden, ²Department of Medicine, Karolinska Institute, Stockholm, Sweden, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁷Paris Descartes University, Paris, France, ⁸Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁹Charité University Hospital, Berlin, Germany, ¹⁰EULAR Standing Committee of People with Arthritis/Rheumatism in Europe, Zurich, Switzerland, ¹¹Amsterdam Rheumatology Center, Amsterdam, Netherlands, ¹²Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ¹³Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: To inform the task force for the 2016 update of the EULAR recommendations for the management of RA on the evidence regarding the efficacy…

« Previous Page
1
…
8
9
10
11
12
…
24
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].